Cargando…

Epidemiology and treatment patterns of idiopathic multicentric Castleman disease in the era of IL-6–directed therapy

The epidemiology of human herpesvirus-8–negative/idiopathic multicentric Castleman disease (iMCD) remains incompletely understood. Prior epidemiologic studies of CD and iMCD have been hampered by difficulties in accurate case ascertainment resulting from a lack of uniform diagnostic criteria and a d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Sudipto, Martin, Rabecka, Sande, Brenda, Paige, Jeremy S., Fajgenbaum, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791564/ https://www.ncbi.nlm.nih.gov/pubmed/34535010 http://dx.doi.org/10.1182/bloodadvances.2021004441

Ejemplares similares

Organ dysfunction, thrombotic events and malignancies in patients with idiopathic multicentric castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Correction to: Organ dysfunction, thrombotic events, and malignancies in patients with idiopathic multicentric Castleman disease: a population-level US health claims analysis
por: Mukherjee, Sudipto, et al.
Publicado: (2022)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

Higher rate of progression in HIV(–) than in HIV(+) patients after rituximab for HHV8(+) multicentric Castleman disease
por: Rasmussen, Camille, et al.
Publicado: (2023)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET
por: Mukherjee, S., et al.
Publicado: (2022)

TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy
por: Williams, Corinne, et al.
Publicado: (2021)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Symptom burden in patients with idiopathic multicentric Castleman disease and its impact on daily life: an international patient and caregiver survey
por: Mukherjee, Sudipto, et al.
Publicado: (2023)

Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine
por: Hoffmann, Christian, et al.
Publicado: (2022)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
por: Nabel, Christopher S., et al.
Publicado: (2019)

COVID-19 and blood cancer in the vaccination era
por: Hicks, Lisa K., et al.
Publicado: (2022)

A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study
por: Visco, Carlo, et al.
Publicado: (2022)

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease
por: Nishikori, Asami, et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

Association between Insufficient Interleukin-6 (IL-6) Inhibition and Worsening Outcomes in COVID-19 and Idiopathic Multicentric Castleman Disease (iMCD), and a Mathematical Model to Predict Optimal Dosing to Completely Block IL-6 Activity
por: Rossi, Jean-Francois, et al.
Publicado: (2021)

Patients with CLL have a lower risk of death from COVID-19 in the Omicron era
por: Niemann, Carsten U., et al.
Publicado: (2022)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy
por: La Mura, Vincenzo, et al.
Publicado: (2023)

PB2708: SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE IN PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN’S DISEASE (IMCD): AN EXPLORATORY ANALYSIS OF THE SURVEY’S INTERNAL CONSTRUCT VALIDITY
por: Franklin, Matt, et al.
Publicado: (2023)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan
por: Masaki, Yasufumi, et al.
Publicado: (2019)

Castleman's Disease: A Rare Mass in the Pararenal Retroperitoneum that Mimics Other Tumors
por: Xie, Yi, et al.
Publicado: (2017)

Comparison of the effectiveness and safety of direct oral anticoagulants: a nationwide propensity score–weighted study
por: Ingason, Arnar B., et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Systemic lupus erythematosus mimicking idiopathic multicentric Castleman disease: A diagnostic dilemma
por: Gunathilake, KUIS, et al.
Publicado: (2022)

Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis
por: González García, Andrés, et al.
Publicado: (2022)

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post–CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey
por: van Doesum, Jaap A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e92o7mi17th9nabo7afc46v71m